Cargando…

Tailored duration of adjuvant trastuzumab for human epidermal growth factor receptor 2-positive breast cancer

We assumed that the effect of adjuvant trastuzumab on survival is mediated by the treatment time and we conducted this trial-level meta-regression to determine the appropriate length of treatment. Twelve adjuvant trastuzumab trials (from January 2000 to June 2019, consisting of 20,271 patients) were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Ke-Da, Wang, Xin, Chen, Wan-Kun, Fan, Lei, Mo, Miao, Chen, Han
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406512/ https://www.ncbi.nlm.nih.gov/pubmed/32802960 http://dx.doi.org/10.1038/s41698-020-00128-1

Ejemplares similares

Optimum adjuvant trastuzumab duration for human epidermal growth factor receptor-2 positive breast cancer: a network meta-analysis of randomized trials
por: Ma, Ji, et al.
Publicado: (2021)

Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials
por: Hu, Qiancheng, et al.
Publicado: (2020)

Factors Influencing Adjuvant Chemotherapy and Trastuzumab Choice in Older Human Epidermal Growth Factor Receptor 2-positive Breast Cancer Patients
por: Fang, Yan, et al.
Publicado: (2020)

Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK
por: Earl, H.M., et al.
Publicado: (2021)

Adjuvant Trastuzumab Is Required in Human Epidermal Growth Factor Receptor 2-Positive Node-Negative Breast Cancer Patients Regardless of Tumour Size
por: Bender, Laura, et al.
Publicado: (2020)

Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis
por: Zhu, Youwen, et al.
Publicado: (2022)

Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study
por: Gligorov, Joseph, et al.
Publicado: (2022)

High Systemic Immune-Inflammation Index Predicts Poor Survival in Patients with Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer Receiving Adjuvant Trastuzumab
por: Jiang, Li, et al.
Publicado: (2020)

Intrathecal trastuzumab for leptomeningeal carcinomatosis in patients with human epidermal growth factor receptor 2 positive breast cancer
por: Gulia, Seema, et al.
Publicado: (2016)

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A real-world retrospective study in Chinese patients
por: Guo, Jihong, et al.
Publicado: (2019)

Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: a Meta-analysis
por: Shen, Kai, et al.
Publicado: (2016)

Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population
por: Noda-Narita, Shoko, et al.
Publicado: (2019)

Metastatic Dermatosis in Breast Carcinoma on Adjuvant Trastuzumab: Is Skin a Sanctuary Site in Human Epidermal Growth Factor Receptor-2-Amplified Disease?
por: Sehrawat, Amit, et al.
Publicado: (2018)

Durable Response of Human Epidermal Growth Factor Receptor-2-Positive Gastric Adenosquamous Carcinoma to Trastuzumab-Based Chemotherapy
por: Kadowaki, Shigenori, et al.
Publicado: (2014)

Quantifying the Effects of Combination Trastuzumab and Radiation Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
por: Bloom, Meghan J., et al.
Publicado: (2022)

Identification of Genes Predicting Poor Response of Trastuzumab in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
por: Dong, Xinrui, et al.
Publicado: (2022)

Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2–Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine
por: Haslem, Derrick S., et al.
Publicado: (2017)

Efficacy, safety and administration timing of trastuzumab in human epidermal growth factor receptor 2 positive breast cancer patients: A meta-analysis
por: CHEN, YUAN-YUAN, et al.
Publicado: (2016)

Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer
por: Conte, PierFranco, et al.
Publicado: (2020)

Safety and Tolerability of Docetaxel, Cyclophosphamide, and Trastuzumab Compared to Standard Trastuzumab-Based Chemotherapy Regimens for Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
por: Jitawatanarat, Potjana, et al.
Publicado: (2014)

Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2‐Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
por: Al‐Batran, Salah‐Eddin, et al.
Publicado: (2020)

Risk Factors Associated with Trastuzumab-induced Cardiotoxicity in Patients with Human Epidermal Growth Factor Receptor 2-positive Breast Cancer
por: Abdel-Razaq, Wesam, et al.
Publicado: (2019)

Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 – a prospective study
por: Piotrowski, Grzegorz, et al.
Publicado: (2012)

Human epidermal growth factor receptor 2-positive breast cancer: which cytotoxic agent best complements trastuzumab’s efficacy in vitro?
por: Hurrell, Tracey, et al.
Publicado: (2013)

Trastuzumab-Based Combination Chemotherapy in Patients with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Carcinoma ex Pleomorphic Adenoma
por: Arihara, Yohei, et al.
Publicado: (2018)

Pertuzumab and Trastuzumab Emtansine for Human Epidermal Growth Factor Receptor-2–Positive Metastatic Breast Cancer: Contemporary Population-Based Outcomes
por: Lupichuk, Sasha, et al.
Publicado: (2019)

A phase I study of pharmacokinetics of trastuzumab emtansine in Chinese patients with locally advanced inoperable or metastatic human epidermal growth factor receptor 2-positive breast cancer who have received prior trastuzumab-based therapy
por: Ji, Dongmei, et al.
Publicado: (2020)

Effects of lapatinib or trastuzumab, alone and in combination, in human epidermal growth factor receptor 2‐positive breast cancer: a meta‐analysis of randomized controlled trials
por: Xin, Yong, et al.
Publicado: (2016)

Determining the Optimal (Neo)Adjuvant Regimen for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Regarding Survival Outcome: A Network Meta-Analysis
por: Cai, Yu-Wen, et al.
Publicado: (2022)

Phase 1 combination study of Eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer
por: Mukai, Hirofumi, et al.
Publicado: (2014)

Targeted therapy with trastuzumab for epidermal growth factor receptor 2 (HER2)-positive advanced salivary duct carcinoma: A case report
por: Gibo, Takahiko, et al.
Publicado: (2019)

Locoregional therapy with α‐emitting trastuzumab against peritoneal metastasis of human epidermal growth factor receptor 2‐positive gastric cancer in mice
por: Li, Huizi Keiko, et al.
Publicado: (2017)

Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab
por: Ha, Joo Young, et al.
Publicado: (2021)

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study
por: Perez, Edith A., et al.
Publicado: (2017)

Incidence of central nervous system metastases in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with trastuzumab: A meta-analysis
por: Bai, Xue, et al.
Publicado: (2021)

The in vitro influences of epidermal growth factor and heregulin-β1 on the efficacy of trastuzumab used in Her-2 positive breast adenocarcinoma
por: Hurrell, Tracey, et al.
Publicado: (2013)

Long-term combination chemotherapy using eribulin and trastuzumab for three patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
por: Saeki, Toshiaki, et al.
Publicado: (2016)

Impact of Trastuzumab on Ipsilateral Breast Tumor Recurrence for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer after Breast-Conserving Surgery
por: Cheun, Jong-Ho, et al.
Publicado: (2021)

The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers
por: Kim, Hye Ryeon, et al.
Publicado: (2021)

Autophagy flux inhibition augments gastric cancer resistance to the anti-human epidermal growth factor receptor 2 antibody trastuzumab
por: Ye, Hua, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_thqqlj1nochkenrnlj1dshug3t